ERBB2 and breast cancer: Compared with the HER2‐positive breast cancer populations, patients with bone metastases had a higher percentage of solitude (50.7% vs. 39.3%), higher T and N staging, and more additional metastatic sites, especially the liver (37.4% vs. 2.4%) and lung (27.2% vs. 2.0%) (Table 1).